<DOC>
	<DOCNO>NCT02252406</DOCNO>
	<brief_summary>The purpose study determine effect ranolazine different marker cardiometabolic disease woman stable angina angina frequency .</brief_summary>
	<brief_title>Impact Ranolazine Blood Markers Women With Angina Metabolic Syndrome</brief_title>
	<detailed_description>Evaluate ability ranolazine favorably modify thrombogenic , inflammatory , lipogenic , oxidative stress hormonal biomarkers relatively short period time group ethnically diverse woman chronic stable angina metabolic syndrome . Evaluate ability ranolazine favorably decrease angina frequency nitroglycerine use relatively short time group patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Patients chronic stable angina ( &gt; 3 month ) symptomatic &gt; =3 attacks/week evidence base adequate therapy Evidence stable coronary artery disease : MI , PCI CABG &gt; 30 day prior enrollment Angiography show &gt; 50 % stenosis major vessel , branch bypass graft &gt; 30 day Enrollment Abnormal stress MPI nuclear study , DBA stress echo decision treat medically angina remain stable &gt; = 3 month Evidence Metabolic Syndrome : As define ATP III criterion i.e 3/5 follow Abdominal circumference F &gt; 88 cm ( 35 ) , M &gt; 102 cm ( 40 ) Hypertriglyceridemia ≥ 150 mg/dl HDL F &lt; 50 mg/dl M &lt; 40 mg/dl Blood Pressure ≥130/85 Fasting Glucose ≥100 mg/dl For reproductive age woman , negative urine pregnancy test require inclusion criterion meet . Exclusion patient contraindication use RANEXA , include patient CYP3A4 inducers/potent inhibitor , patient liver cirrhosis . Exclusion Patients CrCl &lt; 30 mL/min Limit dose RANEXA 500mg BID patient concurrent diltiazem/verapamil Limit concurrent simvastatin 20 mg/day Limit concurrent metformin 1000 mg/day Additional Exclusion Patients variable inconsistent symptom Patients unstable coronary artery disease revascularization within 30 day enrollment . Patients know severe liver disease . Patients already receive maximal ranolazine therapy 4 week Presence diabetes , hypothyroidism , active infection , cancer and/or recent major surgery illness . Patients contraindication ranolazine see Women reproductive age exclude plan become pregnant next 6 12 month randomization . Patients pregnant lactate Documented allergic reaction ranolazine past . Unexplained prolongation QTc &gt; 500 millisecond . Current plan coadministration moderate CYP3A inhibitor ( eg , diltiazem , verapamil , aprepitant , erythromycin , fluconazole , grapefruit juice grapefruitcontaining product ) full contraindication , meet inclusion criterion otherwise , patient could accept trial dose limit 500 mg BID state previously . Current plan coadministration strong CYP3A inhibitor ( eg , ketoconazole , itraconazole , clarithromycin , nefazodone , nelfinavir , ritonavir , indinavir , saquinavir ) OR strong CYP3A inducer ( eg , rifampin , rifabutin , rifapentine , phenobarbital , phenytoin , carbamazepine , St. John 's Wort ) contraindication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stable Angina</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Women</keyword>
	<keyword>Biomarkers</keyword>
</DOC>